ON4 Stock Overview
Produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Ono Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥13.40 |
| 52 Week High | JP¥18.80 |
| 52 Week Low | JP¥12.60 |
| Beta | 0.18 |
| 11 Month Change | 0% |
| 3 Month Change | 0.75% |
| 1 Year Change | n/a |
| 33 Year Change | -28.72% |
| 5 Year Change | -16.04% |
| Change since IPO | 82.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| ON4 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 0.8% |
| 1Y | n/a | -18.4% | 9.1% |
Return vs Industry: Insufficient data to determine how ON4 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ON4 performed against the German Market.
Price Volatility
| ON4 volatility | |
|---|---|
| ON4 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ON4 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ON4's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1717 | 3,853 | Gyo Sagara | www.ono-pharma.com |
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.
Ono Pharmaceutical Co., Ltd. Fundamentals Summary
| ON4 fundamental statistics | |
|---|---|
| Market cap | €6.11b |
| Earnings (TTM) | €749.12m |
| Revenue (TTM) | €3.10b |
8.2x
P/E Ratio2.0x
P/S RatioIs ON4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ON4 income statement (TTM) | |
|---|---|
| Revenue | JP¥500.33b |
| Cost of Revenue | JP¥126.63b |
| Gross Profit | JP¥373.71b |
| Other Expenses | JP¥252.75b |
| Earnings | JP¥120.95b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 257.54 |
| Gross Margin | 74.69% |
| Net Profit Margin | 24.17% |
| Debt/Equity Ratio | 18.4% |
How did ON4 perform over the long term?
See historical performance and comparisonDividends
3.8%
Current Dividend Yield31%
Payout RatioDoes ON4 pay a reliable dividends?
See ON4 dividend history and benchmarks| Ono Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Sep 27 2024 |
| Dividend Pay Date | Dec 02 2024 |
| Days until Ex dividend | 60 days |
| Days until Dividend pay date | 6 days |
Does ON4 pay a reliable dividends?
See ON4 dividend history and benchmarks